切换至 "中华医学电子期刊资源库"

中华消化病与影像杂志(电子版) ›› 2023, Vol. 13 ›› Issue (06) : 388 -393. doi: 10.3877/cma.j.issn.2095-2015.2023.06.005

论著

中老年食管癌患者调强放射治疗期间放射性肺损伤风险模型构建及应用
单秋洁, 孙立柱(), 徐宜全, 王之霞, 徐妍, 马浩, 刘田田   
  1. 223600 江苏省,徐州医科大学附属沭阳医院肿瘤科
  • 收稿日期:2023-06-12 出版日期:2023-12-01
  • 通信作者: 孙立柱

Construction and application of radiation-induced lung injury risk model for middle-aged and elderly patients with esophageal cancer during intensity modulated radiotherapy

Qiujie Shan, Lizhu Sun(), Yiquan Xu, Zhixia Wang, Yan Xu, Hao Ma, Tiantian Liu   

  1. Department of Oncology, The Affiliated Shuyang Hospital of Xuzhou Medical University, Shuyang 223600, China
  • Received:2023-06-12 Published:2023-12-01
  • Corresponding author: Lizhu Sun
引用本文:

单秋洁, 孙立柱, 徐宜全, 王之霞, 徐妍, 马浩, 刘田田. 中老年食管癌患者调强放射治疗期间放射性肺损伤风险模型构建及应用[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 388-393.

Qiujie Shan, Lizhu Sun, Yiquan Xu, Zhixia Wang, Yan Xu, Hao Ma, Tiantian Liu. Construction and application of radiation-induced lung injury risk model for middle-aged and elderly patients with esophageal cancer during intensity modulated radiotherapy[J]. Chinese Journal of Digestion and Medical Imageology(Electronic Edition), 2023, 13(06): 388-393.

目的

构建中老年食管癌患者调强放射治疗(IMRT)期间放射性肺损伤(RILT)风险模型,并探索其应用价值。

方法

选取徐州医科大学附属沭阳医院2018年1月至2023年1月收治的194例拟行IMRT的中老年食管癌患者,按照3∶1分别纳入模型组(n=145)、验证组(n=49)。记录2组患者RILT发生率,使用Logistic多因素回归分析,总结影响模型组患者RILT发生的风险因素,并基于风险因素建立Nomogram预测模型;计算模型组、验证组模型应用效能,并使用Kolmogorov-Smimov拟合优度检验、决策曲线分析,评估模型校准度和净收益率。

结果

模型组RILT发生率为14.48%(21/145),验证组为16.33%(8/49),组间比较差异无统计学意义(χ2=0.098,P=0.754)。Logistic多因素回归模型分析显示,年龄≥65岁、KPS评分<80分、放疗总剂量≥50 Gy、同步化疗、合并糖尿病,以及肺V5≥55%、V10≥38%、V20≥28%、V30≥20%、肺平均剂量≥13 Gy,均为导致中老年食管癌患者IMRT期间RILT发生的独立风险因素(P均<0.05)。基于风险因素分析建立的Nomogram模型的效能良好,Kolmogorov-Smimov拟合优度检验示模型校准度佳(χ2=5.604,P=0.779),决策曲线分析示该模型区分度良好。

结论

中老年食管癌患者IMRT期间RILT发生风险较高,与患者年龄、活动能力、治疗方案、合并症、肺放射计量学等多种因素有关,基于上述因素建立的预测模型能够为RILT风险预测提供可靠参考,开展风险评估并施加干预能够取得良好获益。

Objective

To construct a risk model of radiation-induced lung injury(RILT)in middle-aged and elderly patients with esophageal cancer during intensity-modulated radiotherapy(IMRT), and to explore its application value.

Methods

From January 2018 to January 2023, 194 middle-aged and elderly patients with esophageal cancer who were treated with IMRT were selected from the Affiliated Shuyang Hospital of Xuzhou Medical University, and were divided into model group(n=145)and verification group(n=49)according to the ratio of 3∶1.The incidence of RILT in the two groups was recorded, and the risk factors affecting the occurrence of RILT in the model group were summarized by Logistic multivariate regression analysis, and the Nomogram prediction model was established based on the risk factors.The application efficiency of the model group and verification group was calculated, and Kolmogorov-Smimov goodness-of-fit test and decision curve analysis were used to evaluate the model calibration and net yield.

Results

The incidence of RILT was 14.48%(21/145)in the model group and 16.33%(8/49)in the verification group, and there was no statistical difference between the two groups(χ2=0.098, P=0.754). Logistic multivariate regression model analysis showed that age≥65 years, KPS score<80, total radiation dose≥50 Gy, concurrent chemotherapy, diabetes, and lung V5≥55%, V10≥38%, V20≥28%, V30≥20%, and average lung dose≥13 Gy were all independent risk factors for RILT during IMRT in middle-aged and elderly patients with esophageal cancer(all P<0.05). The Nomogram model based on risk factor analysis had good efficiency, Kolmogorov-Smimov goodness-of-fit test showed that the model had good calibration(χ2=5.604, P=0.779), and decision curve analysis showed that the model had good discrimination.

Conclusion

The risk of RILT in middle-aged and elderly patients with esophageal cancer during IMRT is high, and it is related to many factors, such as age, mobility, treatment plan, complications, lung dosimetry and so on.The prediction model based on the above factors can provide reliable reference for RILT risk prediction, and risk assessment and intervention can gain good benefits.

表1 2组肺癌患者临床资料比较
表2 模型组发生与未发生放射性肺损伤患者临床资料比较[例(%)]
组别 例数 年龄 性别 吸烟史 KPS评分 临床分期
45~64岁(n=88) ≥65岁(n=57) 男(n=106) 女(n=39) 有(n=54) 无(n=91) <80分(n=84) ≥80分(n=62) Ⅰ~Ⅱ期(n=64) Ⅲ~Ⅳ期(n=81)
发生 21 5(23.81) 16(76.19) 15(71.43) 6(28.57) 8(38.10) 13(61.90) 17(80.95) 4(19.05) 9(42.86) 12(57.14)
未发生 124 83(66.94) 41(33.06) 91(73.39) 33(26.61) 46(37.10) 78(62.90) 67(54.03) 58(46.77) 55(44.35) 69(55.65)
χ2   14 0.035 0.008 5.34 0.016
P   <0.001 0.852 0.93 0.021 0.898
组别 例数 病灶长度 放疗总剂量 同步化疗 肺V5 肺V10
<6 cm(n=57) ≥6 cm(n=88) <50 Gy(n=90) ≥50 Gy(n=55) 是(n=49) 否(n=96) <55%(n=104) ≥55%(n=41) <38%(n=97) ≥38%(n=48)
发生 21 8(38.1) 13(61.9) 6(28.57) 15(71.43) 12(57.14) 9(42.86) 5(23.81) 16(76.19) 5(23.81) 16(76.19)
未发生 124 49(39.52) 75(60.48) 84(67.74) 40(32.26) 37(29.84) 87(70.16) 99(79.84) 25(20.16) 92(74.19) 32(25.81)
χ2   0.015 11.704 5.984 27.798 20.586
P   0.902 <0.001 0.014 <0.001 <0.001
组别 例数 肺V20 肺V30 肺平均剂量 合并高血压 合并糖尿病
<28%(n=50) ≥28%(n=95) <20%(n=47) ≥20%(n=98) <13 Gy(n=55) ≥13 Gy(n=90) 是(n=37) 否(n=108) 是(n=19) 否(n=126)
发生 21 3(14.29) 18(85.71) 2(9.52) 19(90.48) 3(14.29) 18(85.71) 5(23.81) 16(76.19) 7(33.33) 14(66.67)
未发生 124 47(37.90) 77(62.10) 45(36.29) 79(63.71) 52(41.94) 72(58.06) 32(25.81) 92(74.19) 12(9.68) 112(90.32)
χ2   4.434 5.873 5.832 0.038 6.871
P   0.035 0.015 0.016 0.846 0.009
表3 多因素分析赋值表
表4 影响中老年食管癌患者调强放疗期间放射性肺损伤发生的多因素回归分析结果
图1 预测中老年食管癌患者调强放疗期间发生放射性肺损伤的Nomogram模型
图2 模型决策曲线及验证
表5 Nomogram模型区分度评价和内部验证
1
Käsmann LDietrich AStaab-Weijnitz CA,et al.Radiation-induced lung toxicity-cellular and molecular mechanisms of pathogenesis,management,and literature review[J].Radiat Oncol202015(1):214.
2
Murphy CFDunne TElliott JA,et al.Acute kidney injury after esophageal cancer surgery:incidence,risk factors,and impact on oncologic outcomes[J].Ann Surg2022275(5):e683-e689.
3
刘佳,崔珍.放射性肺损伤研究进展[J].中华全科医学201917(11):1893-1897.
4
滕菲,孙晓静,田媛,等.食管癌三维适形放疗前后肺功能,生活质量的变化及放射性肺炎的影响因素分析[J].现代生物医学进展202121(6):1120-1124.
5
Wang KTepper JE.Radiation therapy-associated toxicity:Etiology,management,and prevention[J].CA Cancer J Clin202171(5):437-454.
6
孙建伟,王强,梁冰花,等.食管癌调强放疗靶区与肺体积比和处方剂量的关系[J].中国辐射卫生202130(3):315-320.
7
Arroyo-Hernández MMaldonado FLozano-Ruiz F,et al.Radiation-induced lung injury:current evidence[J].BMC Pulm Med202121(1):9.
8
孟凡庆,武霞.糖尿病合并食管癌患者采用后程加速超分割放疗所致不良反应及相关因素分析[J].实用肿瘤杂志201934(6):519-523.
9
袁成,刘明锐,施林心,等.胸段食管癌累及野放疗与扩大野放疗对危及器官的辐射剂量学分析[J].中国辐射卫生202231(2):210-213.
10
Jayaprakasam VSYeh RKu GY,et al.Role of imaging in esophageal cancer management in 2020:update for radiologists[J].Am J Roentgenol2020215(5):1072-1084.
11
Zhou JWu PSun H,et al.Lung tissue extracellular matrix-derived hydrogels protect against radiation-induced lung injury by suppressing epithelial-mesenchymal transition[J].J Cell Physiol2020235(3):2377-2388.
12
闫俊坜,马学志,李本永.食管癌患者三维适形放射治疗后放射性肺损伤与肺低剂量区受照体积的关系[J].分子影像学杂志202144(3):552-555.
13
Ullah TPatel HPena GM,et al.A contemporary review of radiation pneumonitis[J].Curr Opin Pulm Med202026(4):321-325.
14
常晓龙,文景丽,桑茂忠,等.食管癌和肺癌患者血清TGF-β1,PDGF-B,IL-10预测放射性肺炎的初步临床观察[J].广州医药201950(4):17-22.
15
Semenkovich TRSubramanian MYan Y,et al.Adjuvant therapy for node-positive esophageal cancer after induction and surgery:a multisite study[J].Ann Thorac Surg2019108(3):828-836.
16
熊中奎,郎娟,王思本.放射性肺损伤的影响因素的研究进展[J].中国医药导报202118(21):42-45.
17
汪盛,王彩莲,范丽华.老年食管癌患者三维适形放疗后发生放射性肺炎与剂量体积参数的相关性[J].肿瘤防治研究202148(2):173-177.
18
Uhlenhopp DJThen EOSunkara T,et al.Epidemiology of esophageal cancer:update in global trends,etiology and risk factors[J].Clin J Gastroenterol202013(6):1010-1021.
[1] 张磊磊, 蒋方, 徐疾飞, 周真文, 郭志文, 毕满华. 乳头状肾细胞癌预后预测模型的构建及验证[J]. 中华腔镜泌尿外科杂志(电子版), 2023, 17(04): 343-350.
[2] 高加林, 曹亚娟. 腹腔镜解剖性肝右后叶切除治疗食管癌根治术后孤立性肝转移[J]. 中华腔镜外科杂志(电子版), 2023, 16(04): 239-242.
[3] 施我大, 张亚军, 施展, 吴纪祥, 常绘文, 易忠权, 梁晓东, 周晶晶, 宋建祥. Treg细胞通过上调TGF-β1和B7-H3表达促进食管癌细胞增殖、迁移和侵袭[J]. 中华细胞与干细胞杂志(电子版), 2023, 13(02): 65-75.
[4] 林文斌, 郑泽源, 郑文能, 郁毅刚. 外伤性脾破裂腹腔镜脾切除术患者中转开腹风险预测模型构建[J]. 中华肝脏外科手术学电子杂志, 2023, 12(06): 619-623.
[5] 侯超, 潘美辰, 吴文明, 黄兴广, 李翔, 程凌雪, 朱玉轩, 李文波. 早期食管癌及上皮内瘤变内镜黏膜下剥离术后食管狭窄的危险因素[J]. 中华消化病与影像杂志(电子版), 2023, 13(06): 383-387.
[6] 苏鹏, 吕会来, 温士旺, 黄超, 张缜, 田子强. 全腔镜下食管癌根治术围手术期呼吸系统并发症发生的危险因素分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 294-298.
[7] 曹旬旬, 费素娟. 食管癌患者肿瘤组织CXCL5和CXCR2的表达与病情和预后的相关性分析[J]. 中华消化病与影像杂志(电子版), 2023, 13(05): 299-304.
[8] 屠松霞, 郑红艳, 朱姝, 徐夏君. 食管癌术后患者肠内营养耐受不良的影响因素及列线图风险模型[J]. 中华消化病与影像杂志(电子版), 2023, 13(02): 73-77.
[9] 袁耒, 邹志强, 李传海, 刘玉, 徐瑞鑫, 杜以营. 早期食管癌的光动力治疗[J]. 中华消化病与影像杂志(电子版), 2022, 12(05): 306-309.
[10] 陈柯豫, 黄艳齐, 张玲利. 同时性多发早期食管癌及高级别上皮内瘤变的危险因素分析[J]. 中华临床医师杂志(电子版), 2023, 17(05): 524-528.
[11] 孙天宇, 王如文, 蒋彬. 食管碰撞癌1例[J]. 中华胸部外科电子杂志, 2023, 10(04): 238-240.
[12] 李正龙, 赵永生, 罗钶鑫, 彭忠勤. 胸腔镜切除治疗全内脏反位合并食管癌手术1例并文献复习[J]. 中华胸部外科电子杂志, 2023, 10(04): 234-237.
[13] 秦建军, 郭旭峰, 胡杨, 李向楠, 李卓毅, 林江波, 梅新宇, 唐鹏, 王长春, 王枫, 王洪琰, 尹俊, 袁勇, 赵晋波, 李志刚, 李印. 日本2022版食管癌诊治指南在中国的接受度——中国红杉树专家调研[J]. 中华胸部外科电子杂志, 2023, 10(04): 195-199.
[14] 李国仁, 戴建华. 我国食管癌治疗理念与模式的沿革和进展[J]. 中华胸部外科电子杂志, 2023, 10(02): 117-125.
[15] 朱开元, 李志刚. 食管癌术后吻合口瘘临床管理进展[J]. 中华胸部外科电子杂志, 2023, 10(01): 50-56.
阅读次数
全文


摘要